Altimmune
Latest round
- Series B
Last raised
- Jul 2004
Total raised
- $10M
Investors
- 1
About Altimmune
Altimmune, Inc.Founded in 1997 and headquartered in Gaithersburg, US, Altimmune, Inc. specializes in developing innovative therapeutics. The company underwent a pivotal change in 2017 when Truffle Capital exited through a merger with Pharmathene, Inc. Following this, HealthCap and Novartis Venture Fund exited their stake through an IPO.Altimmune is dedicated to developing peptide-based therapeutics, primarily focusing on Pemvidutide, aimed at tackling obesity and related metabolic issues. This growth strategy includes expanding partnerships with healthcare providers and exploring new markets to maximize its therapeutic offerings.
Who invested in Altimmune
1 investor across 1 round
See all investors in Altimmune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jul 1, 2004
Amount
$10M
Investors
Questions about Altimmune
Who invested in Altimmune?
Altimmune has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Altimmune raised?
Altimmune has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Altimmune last raise money?
Altimmune's most recent round on record is a Series B, in Jul 2004.
What does Altimmune do?
Altimmune is a biotechnology company.
Where is Altimmune headquartered?
Altimmune is headquartered in Gaithersburg, US.
Which VCs invest in companies like Altimmune?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Altimmune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Altimmune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.